Skip to main content
. Author manuscript; available in PMC: 2018 Oct 3.
Published in final edited form as: Cell Metab. 2017 Oct 3;26(4):633–647.e7. doi: 10.1016/j.cmet.2017.09.009

Figure 6. MYC and MCL1 cooperate to expand CSCs.

Figure 6

(A, C) Cells were transduced with MYC and/or MCL1. After 4 days, cells were seeded in mammosphere assays for 7 days (*p<0.05, **p<0.005, ***p<0.0005). (B, D) Proportion of ALDH+ or CD44hi/CD24low cells was determined by flow cytometry (*p<0.05, **p<0.005, ***p<0.0005). (E, F) MDA-MB-468 cells transduced with pLX302-GFP or -MCL1 were re-transduced with pINDUCER20-MYC. Cells were then seeded in a mammosphere assay for 7 days ± 100 ng/mL DOX (E). Proportion of CD44hi/CD24low cells was determined by flow cytometry after 4 days of treatment with DOX (F). (G) OCRs were determined by Seahorse XFe96 extracellular flux analyzer. (H) ROS levels were examined by ROS-Glo (*p<0.05, **p<0.005, ***p<0.0005). (I) GSVA score was examined with a gene set [Reactome_Pyruvate metabolism and Citric Acid (TCA) cycle] in breast cancers in TCGA (*p<0.0005). Data are represented as mean ± SD.